Poland· PL-100350116
Monural
A fosfomycin product containing fosfomycinum trometamolum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Fosfomycin is registered in 17 of 19 countries.
Countries holding a registration under ATC J01XX01 (fosfomycin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Fosfomycin · ATC J01XX01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of fosfomycin costs, country by country.
Normalised to the WHO defined daily dose (3 g), the median price runs from $3.86 in Spain to $16.40 in Switzerland — a ×4.2 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Fosfomycin · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$16.40
- ES Spain$3.86
The record
At a glance
URPL (Poland)- Active substance
- Fosfomycinum trometamolum
- Manufacturer
- Delfarma Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- J01XX01
- ATC class
- Fosfomycin
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991231651
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for fosfomycin.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fosfomycin · interactions on record
3 records
- 2 moderate
- 1 minor
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- BalsalazideA07EC04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01XX01
Fosfomycin, as other registers publish it.
- PolandAfasturalExeltis Poland Sp. z o.o.
- GermanyAfosfolAxunio Pharma Gmbh
- United KingdomAlexi 3g granules for oral solution sachetsNordic Pharma Ltd
- ItalyBERNYFIDIA SPECIALTY S.R.L.
- United StatesContepoMeitheal Pharmaceuticals Inc.
- ItalyDAFOCISTARISTO PHARMA GMBH
- ItalyDANIFOSPHARMACARE S.R.L.
- PolandFasflowAurovitas Pharma Polska Sp. z o.o.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0ec7bf7-10ea-465f-bdf9-e7f522292d58 GET /v1/drugs/c0ec7bf7-10ea-465f-bdf9-e7f522292d58?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granulat do sporządzania roztworu doustnego",
"source": "urpl",
"strength": "3 g",
"packaging": "05909991231651 ¦ Rp ¦ 109911\n1 sasz. 8 g",
"substance": "Fosfomycinum 3 g",
"common_name": "Fosfomycinum trometamolum",
"pl_product_id": "100350116",
"pozwolenie_nr": "486/15",
"auth_procedure": "IR",
"authorisation_validity": "2025-07-21"
}See everything about fosfomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.